R James White

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7850755/publications.pdf Version: 2024-02-01



R IAMES WHITE

#	Article	IF	CITATIONS
1	Tadalafil Therapy for Pulmonary Arterial Hypertension. Circulation, 2009, 119, 2894-2903.	1.6	956
2	Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. New England Journal of Medicine, 2015, 373, 834-844.	27.0	906
3	Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension. Circulation, 2013, 127, 624-633.	1.6	291
4	Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: A placebo-controlled trial. Journal of Heart and Lung Transplantation, 2010, 29, 137-149.	0.6	180
5	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respiratory Medicine,the, 2019, 7, 227-238.	10.7	122
6	Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2007, 293, L583-L590.	2.9	116
7	Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 707-717.	5.6	89
8	Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis–associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 209-221.	5.6	88
9	Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension. Liver Transplantation, 2009, 15, 30-36.	2.4	86
10	Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. Lancet Respiratory Medicine,the, 2021, 9, 573-584.	10.7	85
11	Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. Lancet Respiratory Medicine,the, 2016, 4, 894-901.	10.7	59
12	Transition from parenteral to oral treprostinil in pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2017, 36, 193-201.	0.6	50
13	Thrombosis, platelets, microparticles and PAH: more than a clot. Drug Discovery Today, 2014, 19, 1230-1235.	6.4	42
14	Customized Internal Reference Controls for Improved Assessment of Circulating MicroRNAs in Disease. PLoS ONE, 2015, 10, e0127443.	2.5	42
15	The impact of a pulmonary embolism response team on the efficiency of patient care in the emergency department. Journal of Thrombosis and Thrombolysis, 2019, 48, 331-335.	2.1	34
16	Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 834-842.	0.9	31
17	Pharmacokinetics of Oral Treprostinil Sustained Release Tablets During Chronic Administration to Patients with Pulmonary Arterial Hypertension. Journal of Cardiovascular Pharmacology, 2013, 61, 474-481.	1.9	30
18	Subcutaneous Treprostinil is Well Tolerated with Infrequent Site Changes and Analgesics. Pulmonary Circulation, 2013, 3, 611-621.	1.7	29

R JAMES WHITE

#	Article	IF	CITATIONS
19	Recommendations for the use of oral treprostinil in clinical practice: a Delphi consensus project pulmonary circulation. Pulmonary Circulation, 2017, 7, 167-174.	1.7	29
20	Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 751-760.	5.6	27
21	Chronic therapeutic anticoagulation is associated with decreased thrombotic complications in SARSâ€CoVâ€2 infection. Journal of Thrombosis and Haemostasis, 2020, 18, 2640-2645.	3.8	26
22	Thrombin induces fibronectin-specific migration of pulmonary microvascular endothelial cells: requirement of calcium/calmodulin-dependent protein kinase II. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 297, L706-L714.	2.9	20
23	Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respiratory Medicine,the, 2022, 10, 35-46.	10.7	17
24	Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension. Respiratory Research, 2019, 20, 208.	3.6	16
25	Tumor Necrosis Factor Induces Obliterative Pulmonary Vascular Disease in a Novel Model of Connective Tissue Disease–Associated Pulmonary Arterial Hypertension. Arthritis and Rheumatology, 2020, 72, 1759-1770.	5.6	14
26	Low dose monocrotaline causes a selective pulmonary vascular lesion in male and female pneumonectomized rats. Experimental Lung Research, 2018, 44, 51-61.	1.2	13
27	Direct oral anticoagulant therapy in patients with morbid obesity after intermediate- or high-risk pulmonary emboli. ERJ Open Research, 2021, 7, 00554-2020.	2.6	13
28	Novel Analysis of the Oral Treprostinil Combination Therapy Trial Data. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1434-1436.	5.6	12
29	Tissue Factor Is Induced in a Rodent Model of Severe Pulmonary Hypertension Characterized by Neointimal Lesions Typical of Human Disease. Chest, 2005, 128, 612S-613S.	0.8	11
30	Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy, 2011, 12, 2583-2593.	1.8	11
31	Reduced Notch1 Cleavage Promotes the Development of Pulmonary Hypertension. Hypertension, 2022, 79, 79-92.	2.7	11
32	Heart Rate Expenditure Correlates with Right Ventricular Function. Annals of the American Thoracic Society, 2020, 17, 372-375.	3.2	10
33	A Pharmacokinetic and Tolerability Comparison in Subjects Transitioning From Twice Daily to Three Times Daily Dosing of Oral Treprostinil. Chest, 2014, 146, 865A.	0.8	9
34	Estrogen: Friend or Foe in Pulmonary Hypertension?. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1084-1086.	5.6	9
35	Clinical and imaging outcomes after intermediate―or highâ€risk pulmonary embolus. Pulmonary Circulation, 2020, 10, 1-9.	1.7	9
36	Oral treprostinil improves pulmonary vascular compliance in pulmonary arterial hypertension. Respiratory Medicine, 2022, 193, 106744.	2.9	8

R JAMES WHITE

#	Article	IF	CITATIONS
37	Heart rate monitoring improves clinical assessment during 6-min walk. Pulmonary Circulation, 2020, 10, 204589402097257.	1.7	7
38	Liver Backscatter and the Hepatic Vasculature's Autocorrelation Function. Acoustics, 2020, 2, 3-12.	1.4	7
39	New Therapeutic Approaches in Pulmonary Arterial Hypertension. Circulation, 2018, 137, 2390-2392.	1.6	5
40	Clinical trial design in phase 2 and 3 trials for pulmonary hypertension. Pulmonary Circulation, 2020, 10, 1-10.	1.7	5
41	Traversing and labeling interconnected vascular tree structures from 3D medical images. , 2014, , .		4
42	Assessment of the REPLACE study composite endpoint in riociguatâ€ŧreated patients in the PATENT study. Pulmonary Circulation, 2020, 10, 1-8.	1.7	4
43	Venous thromboembolism associates with SARS-CoV-2 more than seasonal influenza. Thrombosis Research, 2021, 205, 40-43.	1.7	4
44	Pulmonary arterial hypertension: building a better mouse trap for 2010. Drug Discovery Today: Therapeutic Strategies, 2004, 1, 351-359.	0.5	3
45	Drug discovery in pulmonary arterial hypertension: attacking the enigmatic root of a deadly weed. Drug Discovery Today, 2014, 19, 1226-1229.	6.4	3
46	Vasodilator use in precapillary pulmonary hypertension with end stage kidney disease: A single center experience. Respiratory Medicine, 2021, 188, 106596.	2.9	3
47	Update on the Development of Oral Prostacyclin Analogs for the Treatment of PAH. Advances in Pulmonary Hypertension, 2009, 8, 32-36.	0.1	3
48	Comparison of chest- and wrist-based actigraphy in pulmonary arterial hypertension. European Heart Journal Digital Health, 2022, 3, 90-97.	1.7	3
49	Combination therapy improves vascular volume in female rats with pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 317, L445-L455.	2.9	2
50	Evaluation of Clinical Recovery After Surgical Treatment for Hand Ischemia From Vasospastic and Occlusive Disease Using PROMIS. Hand, 2023, 18, 15-21.	1.2	2
51	8% Capsaicin Patch as Analgesia for Severe Treprostinil Infusion Site Pain. Pain Medicine, 2017, 18, 2515-2517.	1.9	1
52	Longâ€ŧerm study of oral treprostinil to treat pulmonary arterial hypertension: dosing, tolerability, and pharmacokinetics. Pulmonary Circulation, 2020, 10, 1-9.	1.7	1
53	Resting heart rate as a surrogate for improvement in intermediate risk pulmonary embolus patients?. Respiratory Medicine, 2021, 187, 106578.	2.9	1
54	An Untapped Resource: Characteristics of Thrombus Recovered from Intermediate or High Risk Pulmonary Embolus Patients. Cardiovascular Pathology, 2021, 57, 107392.	1.6	1

#	Article	IF	CITATIONS
55	Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension. Respiratory Medicine Case Reports, 2022, 37, 101646.	0.4	1
56	P0229APPLICATION OF A RISK MITIGATION STRATEGY TO PREVENT EXCESS CARDIOVASCULAR RISK IN PULMONARY HYPERTENSION: LARIAT STUDY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
57	Selexipag Use in Clinical Practice. Chest, 2020, 157, 761-763.	0.8	0
58	Guest Editor's Memo. Advances in Pulmonary Hypertension, 2012, 11, 2-48.	0.1	0